Skip to main content
. 2015 Aug 25;10(8):e0136563. doi: 10.1371/journal.pone.0136563

Fig 6. Deferiprone inhibits histopathological signs in skin of CKDmice.

Fig 6

(A) Histopathological findings in the skin of mice with CKD and CKD mice treated with 125 mg/kg deferiprone for 16 weeks. Representative images are of dorsal skin biopsies of each group at 200X magnification H&E stained sections. (B) A box-whisker chart shows the data of the dermal thickness for the sham, CKD, CKD mice with deferiprone (n = 4 for sham, n = 10 for CKD, n = 12 for CKD mice treated with deferiprone). Data shows there was no significant difference between CKD and mice treated with deferiprone, NS = not significant. Box: 25–75 percentile; whiskers: 5–95 percentile; horizontal line: median, square: mean. The significance of differences among groups was evaluated by a one-way analysis of variance (ANOVA) and with a posthoc Tukey-Kramer test.